Literature DB >> 12017315

Quantification of sensitivity of endothelial cell markers for the astrocytoma and oligodendroglioma tumours.

Dhana E Aronsson1, Carin Muhr.   

Abstract

Angiogenesis, the formation of new blood vessels, is necessary for tumour growth. The aim of this study was to quantify the sensitivity of five endothelial cell markers CD31/CD34-mix, CD31, CD34, lectin UEA-1 and FVIII-rag. Paraffin-embedded tumour tissue from 15 patients with astrocytomas grades II-IV and oligodendrogliomas grades II-III was used Sections of 2 microm were stained. Seven serial sections from each of the 15 tumours enabled consecutive examination of the vessels with all five markers and with two interposed hematoxylin-eosin (H&E) sections as controls. Among the endothelial cell markers, the mix CD31/CD34 showed the highest sensitivity with 79% and 99%, respectively, when applied in astrocytomas grade II and grades III-IV and 86% when applied in oligodendrogliomas. The study has shown that the sensitivity of the five endothelial cell markers varied. The mix CD31/CD34 was superior and seems to be a useful marker for quantification of angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12017315

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway.

Authors:  Jason T Huse; Matija Snuderl; David T W Jones; Carole D Brathwaite; Nolan Altman; Ehud Lavi; Richard Saffery; Alexandra Sexton-Oates; Ingmar Blumcke; David Capper; Matthias A Karajannis; Ryma Benayed; Lukas Chavez; Cheddhi Thomas; Jonathan Serrano; Laetitia Borsu; Marc Ladanyi; Marc K Rosenblum
Journal:  Acta Neuropathol       Date:  2016-11-03       Impact factor: 17.088

2.  A tale of two multi-focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone-based OKN-007.

Authors:  Michelle Zalles; Nataliya Smith; Debra Saunders; Megan Lerner; Kar-Ming Fung; James Battiste; Rheal A Towner
Journal:  J Cell Mol Med       Date:  2021-12-14       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.